Literature DB >> 23838921

Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma.

Ming-Huang Chen1, Yi-Hua Jan, Peter Mu-Hsin Chang, Yung-Jen Chuang, Yi-Chen Yeh, Hao-Jan Lei, Michael Hsiao, Shiu-Feng Huang, Chi-Ying F Huang, Gar-Yang Chau.   

Abstract

BACKGROUND: Serum Golgi membrane protein 1 (GOLM1) is a novel biomarker for hepatocellular carcinoma (HCC). However, few studies have investigated the relationship between GOLM1 protein expression and clinicopathologic features in HCC patients. The aim of this study was to investigate the expression of GOLM1 in human HCC and its correlation with clinicopathologic parameters.
METHODS: Clinicopathologic data were obtained through a detailed retrospective review of the medical records of 193 patients with HCC who had undergone surgical resection between 1990 and 2006 at the Taipei Veterans General Hospital. Another 120 HCC tissue samples provided by the Taiwan Liver Cancer Network were used as validation cohort. Immunohistochemical staining was used to determine the expression of GOLM1 in archived formalin-fixed, paraffin-embedded tissue specimens.
RESULTS: GOLM1 expression was significantly higher in resected HCC tumor tissues than in corresponding normal liver tissues (p < 0.01). After a median follow-up of 51 months, multivariate analysis showed that portal vein invasion (hazard ratio [HR], 1.515; 95 % confidence interval [95 % CI], 1.008-2.277; p = 0.046) and high GOLM1 protein expression (HR, 1.696; 95 % CI, 1.160-2.479; p = 0.006) were independent prognostic factors for poor overall survival. High GOLM1 protein expression still significantly correlates with worse overall survival as well as disease-free survival in the validation cohort (p < 0.001 and p = 0.002).
CONCLUSIONS: Overexpression of GOLM1 is associated with poor prognosis in human HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23838921     DOI: 10.1245/s10434-013-3101-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma.

Authors:  Jian Yin; Peng Hou; Zhiqiang Wu; Tao Wang; Yanxiao Nie
Journal:  Tumour Biol       Date:  2015-01-25

2.  MiR-30a-3p Suppresses the Growth and Development of Lung Adenocarcinoma Cells Through Modulating GOLM1/JAK-STAT Signaling.

Authors:  Dongxiao Ding; Yunqiang Zhang; Xuede Zhang; Ke Shi; Wenjun Shang; Junjie Ying; Li Wang; Zhongjie Chen; Haihua Hong
Journal:  Mol Biotechnol       Date:  2022-04-19       Impact factor: 2.860

3.  Down-expression of GOLM1 enhances the chemo-sensitivity of cervical cancer to methotrexate through modulation of the MMP13/EMT axis.

Authors:  Rui Min Li; Man Man Nai; She Jiao Duan; Shu Xing Li; Bao Na Yin; Fang An; Yao Qing Zhai; Jie Liu; Yan Rong Chu; Yang Yu; Wen Yue Song
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

4.  Overexpression of golgi membrane protein 1 promotes non-small-cell carcinoma aggressiveness by regulating the matrix metallopeptidase 13.

Authors:  Li Mei Li
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

5.  CXCL10 decreases GP73 expression in hepatoma cells at the early stage of hepatitis C virus (HCV) infection.

Authors:  Yuan Liu; Ziying Zou; Bing Zhu; Zonghai Hu; Ping Zeng
Journal:  Int J Mol Sci       Date:  2013-12-13       Impact factor: 5.923

6.  Diagnostic and prognostic serum marker of cholangiocarcinoma (Review).

Authors:  Xiaojun Zeng; Hualin Tao
Journal:  Oncol Lett       Date:  2014-11-10       Impact factor: 2.967

7.  Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion.

Authors:  Di Jin; Jun Tao; Dan Li; Yanan Wang; Li Li; Zhongdong Hu; Zhenzhen Zhou; Xiuli Chang; Chunfeng Qu; Hongbing Zhang
Journal:  Oncotarget       Date:  2015-10-20

Review 8.  Recent advances of GOLM1 in hepatocellular carcinoma.

Authors:  Jiuliang Yan; Binghai Zhou; Hui Li; Lei Guo; Qinghai Ye
Journal:  Hepat Oncol       Date:  2020-06-29

9.  Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.

Authors:  Xi Liu; Lei Chen; Tao Zhang
Journal:  Cancer Control       Date:  2018 Jan-Mar       Impact factor: 3.302

10.  Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma.

Authors:  Zhu-qing Zhang; Hua Meng; Nan Wang; Li-na Liang; Li-na Liu; Shu-ming Lu; Yong Luan
Journal:  Diagn Pathol       Date:  2014-07-02       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.